La curietherapie prostatique: realites et perspectives

[en] The paper presents the characteristics, the place and the limits of brachytherapy in prostate radiotherapy. While sparing the rectal wall, erectile function as well as urinary continence, I(125) and Pd(103) permanent implants represent interesting approaches for good prognosis tumours in comparison to surgery or conformal external beam radiotherapy with similar cure rates. Overcoming easily the problems of organ motion and patient positioning while allowing doses per fraction as high as 10 Gy, brachytherapy is an excellent boosting method in the treatment of intermediate or unfavourable prognosis tumours of which alpha/beta is 1,5 Gy. Encouraging biological control rates of 80-90% have been published in phase II trials. Compared to external beam radiotherapy, the heterogeneity of irradiation inside the clinical target volume should increase the probability of cure as for a specific dose, a significant part will be overdosed. So far, 120-130% of the prescribed doses are delivered to the peripheral zone at the origin of 70% of tumours. On the opposite, this heterogeneity is inducing an overdosage of the urethral bed at the price of higher toxicity levels in situations of previous obstructive syndrome and urethral stenosis. A better integration of the therapeutic modalities available, brachytherapy included, should increase our curative possibilities in the radiation treatment of prostatic cancer.

Disciplines :

Oncology

Author, co-author :

Nickers, Philippe ; Université de Liège - ULiège > Département des sciences cliniques > Radiothérapie Oncologie > Chef de Clinique

Deneufbourg, Jean-Marie ; Université de Liège - ULiège > Faculté de médecine > Radiothérapie Oncologie > Chargé de cours CHU Chef de Service

Language :

French

Title :

La curietherapie prostatique: realites et perspectives

Alternative titles :

[en] Prostate Brachytherapy: Current States and Future Prospects

Publication date :

August 2003

Journal title :

Cancer Radiotherapie

ISSN :

1278-3218

eISSN :

1769-6658

Publisher :

Elsevier, Amsterdam, Netherlands

Volume :

Issue :

Pages :

266-73

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 March 2022

Statistics

Number of views

45 (7 by ULiège)

Number of downloads

40 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Blasko JC. Brachytherpay. Urology 2000;55:306-8.
Chauveinc L, Flam T, Servois V, N'Guyen D, Rosenwald JC. La curiethérapie prostatique : une alternative thérapeutique. Revue de la littérature. Cancer Radiother 2000;4:253-64.
D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998;280:969-74.
Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
Galalae R, Martinez A, Mate T, Mitchell C, Edmundson G, Nurnberg N, et al. Long-Term Outcome by Risk Factors Using Conformal High Dose Rate (HDR) Boost for Prostate Cancer. Int J Radiat Oncol Biol Phys 2002;54(S):36-7.
Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46:823-32.
Hsu IJ, Pickett B, Shinohara K, Krieg R, Roach M, Phillips TH. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. Int J Radiat Oncol Biol Phys 2000;46:851-8.
Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, et al. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:261-8.
International Commission on Radiation Units Measurements. Report 50: prescribing, recording and reporting photon beam therapy Washington DC. 1993.
King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys 2000;46:165-72.
Kramer NM, Hanlon AL, Horwitz EM, Pinover WH, Hanks GH. Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumours treated with 3 dimensional conformal radiation therapies. Int J Radiat Oncol Biol Phys 2002;53:277-81.
Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimentional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont Phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 2000;47:343-52.
Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high dose rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001;49:61-9.
Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, et al. Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-27.
Martinez AA, Yan D, Brabbins D, Lockman D, Wallace M, Edmundson G, et al. Dose escalation in prostate cancer: a comparison of RTOG chronic toxicities for patients treated in the adaptive external beam process with 3D-Conformal or IMRT vs external beam plus conformal HDR brachytherapy boost. Int J Radiat Oncol Biol Phys 2002;54(S):318.
Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998;41:525-33.
Nickers P, Coppens L, Beauduin M, Darimont M, de Leval J, Deneufbourg JM. Feasibility study combining low dose rate 192 Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma. Radioth Oncol 2000;55:41-7.
Nickers P, Coppens L, Beauduin M, Sabatier J, Albert A, de Leval J, et al. PSA kinetics after external beam radiotherapy alone or combined with an Iridium brachytherapy boost to deliver 85 Gy to prostatic adenocarcinoma. Strahlen Onkol 2001;177:90-5.
Niehoff P, Loch T, Galalae R, Thiemann O, Nurnberg N, Kohr P, et al. HDR Brachytherapy treatment for local recurrence after radical prostatectomy: first results and experiences. Radioth Oncol 2000;55(S1):44-5.
Niemierko A. Reporting and analysing dose distributions: a concept of equivalent uniform dose. Med Phys 1997;24:103-10.
Padhani AR, Khoo VS, Suckling J, Minst P, Husband JE, Leach MO, et al. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys 1999;44:525-33.
Pollack A, Zagars GK, Starckschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
Potters L, Kattan MW, Reddy CA, Klein EA, Ciezki JP, Reuther AM, et al. Monotherapy for Stage T1/T2 Prostate Cancer: Radical Prostatectomy, External Beam Radiotherapy, or Permanent Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2002;54(S):9.
Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern Prostate Brachytherapy. Cancer 2000;89:135-41.
Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-8.
Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology 2000;55:382-6.
Stroom JC, De Boer HCJ, Huizenga H, Visser AG. Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. Int J Radiat Oncol Biol Phys 1999;43:905-19.
Sylvester J, Blasko JC, Grimm PD, Meier R, Goy B, Colburn O, Cavanagh W. Neo-adjuvant androgen ablation combined with external-beam radiation therapy and permanent interstitial brachytherapy boost in localized prostate cancer. Mol Urol 1999;3:231-6.
Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radio-active seed implantation of the prostate. J Urol 1998;160:1379-82.
Van de Voorde WM. Pathology of the prostate. Carcinoma of the prostate. Innovations in management. Springer-Verlag; 1996. p. 27-50.
Van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1121-35.
Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6.